Press Release

OrchidPharm~W -- A Dhanuka Group Company ---------------------------------- October 24, 2026 National Stock Exchange of India Limited, BSE Limited Exchange Plaza, Bandra Kurla Complex, Phiroze Jeejeebhoy Towers, Dalal Bandra (E), Mumbai-400051 Street Fort, Mumbai- 400001 Symbol: ORCHPHARMA Scrip Code: 524372 Subject: Announcement under Regulation 30 regarding the licensing and supply agreement with Laboratorio Libra S.A.("Libra"} Dear Sir/Madam, In accordance to Regulation 30 read with Part A of Schedule III of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, this is to inform that the Company has entered into a licensing and supply agreement with Libra. Press Release dated October 24, 2026 titled as "Orchid Pharma Expands Exblifep® (Cefepime/Enmetazobactam) into Latin America through Licensing and Supply Agreement with Libra" is enclosed herewith. You are requested to take the above information on record. Thanking You, For Orchid Pharma Limited KapilOayya Company Secretary & Compliance Officer Membership No.: Fl0698 End: As Above +91-44-27444471/72/73 corporate@orchidpharma.com orchidpharma.com CIN: L24222TN1992PLC022994 Registered Office: Corporate Office: Orchid Pharma Limited 15th Floor, Tower 1. DLF Corporate Greens, Sector 74A, Plot Nos. 121-128, 128A-133, 138-151. 159-164, SIDCO Industrial Estate, Gurugram - 122004, Haryana, India Alathur, Chengalpattu Dist - 603110, Tamil Nadu, India. OrchidPharm~W 24th October, 2026 Orchid Pharma Expands Exblifep® (CefepimelEnmetazobactam) into Latin America through Licensing and Supply Agreement with Libra Orchid Pharma Ltd. (Orchid) and Libra (Libra) have signed a licensing and supply agreement covering Exblifep® (cefepime/enrnetazobactam) across nine Latin American markets. Exblifep is a novel antibiotic combination indicated for complicated urinary tract infections (cUTI) and hospital-acquired and ventilator-associated bacterial pneumonia (HAP/VAP) caused by Gram-negative pathogens. Commercialization in each market is subject to approval by the relevant national regulatory authority. Designed as a carbapenem-sparing option, Exblifep targets serious hospital infections driven by ESBL-producing Gram-negative bacteria. It holds approvals from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), features in the IDSA and EUCAST treatment guidelines, and is the first new chemical entity invented by an Indian pharmaceutical company to secure both approvals. Libra receives exclusive rights to register, import, and market Exblifep in Chile, Costa Rica, Ecuador, EI Salvador, Guatemala, Honduras, Panama, Paraguay, and Uruguay, while Orchid manufactures and supplies the finished dosage form. Over the first 10 years, the partnership is expected to represent a potential commercial opportunity of approximately USD 80 million, based on projected demand across these markets. "Extending Exblifep into Latin America is a priority for Orchid, and Libra is well placed to lead its introduction across these markets. Together, we aim to give clinicians in the region a new option for treating serious Gram-negative hospital infections." - Manish Dhanuka, Managing Director, Orchid Pharma Ltd. "We are honoured to partner with Orchid Pharma to bring Exblifep to Latin America, expanding access to an innovative therapeutic option for patients across the region while contributing to the response to the growing challenge of antimicrobial resistance. "- Carlos Scherschener, CEO, Laboratorio Libra S.A. About Orchid Pharma Limited Orchid Pharma Limited is a fully vertically integrated pharmaceutical company with end-to end capabilities from Key Starting Materials (KSMs) to Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDFs), focused on complex injectable antibiotics. Orchid is the first Indian pharmaceutical company to invent a New Chemical Entity (NCE) approved in both the United States and Europe, with the product commercially marketed in Europe and India. The company operates globally approved manufacturing facilities compliant with USFDA and EU-GMP standards. wyvw.orchidpharma.com +91-44-27444471/72/73 corporate@orchidpharma.com orchidpharma.com CIN: L24222TN1992PLC022994 Registered Office: Corporate Office: Orchid Pharma Limited 15th Floor, Tower 1, DLF Corporate Greens, Sector 74A, Plot Nos. 121-128, 128A-133,138-151, 159-164, SIDCO Industrial Estate, Gurugram - 122004, Haryana, India Alathur, Chengalpattu Dist - 603110, Tamil Nadu, India. OrchidPharm~~ About Libra Founded in Uruguay in 1961, Laboratorio Libra is a Latin American pharmaceutical company focused on providing access to innovative treatments in specialized therapeutic areas, including infectology, critical care, oncology, nutrition, HIV and rare diseases. Libra manufactures and commercializes its own products and represents leading international pharmaceutical companies. Through its offices and commercial network, the company operates across multiple Latin American markets, combining regional regulatory expertise with established capabilities in institutional promotion and distribution. www.lablibra.com Advisors Sathguru Management Consultants acted as exclusive advisor to Orchid Pharma on the transaction. +91-44-27444471/72/73 corporate@orchidpharma.com orchidpharma.com CIN: L24222TN1992PLC022994 Registered Office: Corporate Office: Orchid Pharma Limited 15th Floor, Tower 1, DLF Corporate Greens, Sector 74A, Plot Nos. 121-128, 128A-133, 138-151, 159-164, SIDCO Industrial Estate, Gurugram - 122004, Haryana, India Alathur, Chengalpattu Dist - 603110, Tamil Nadu, India.